OKYO Pharma (NASDAQ:OKYO) Announces Quarterly Earnings Results, Misses Estimates By $5.45 EPS

OKYO Pharma (NASDAQ:OKYO) posted its earnings results on Monday. The company reported ($5.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($5.45), FiscalAI reports.

OKYO Pharma Price Performance

NASDAQ:OKYO traded down $0.03 during trading hours on Monday, reaching $1.41. The company’s stock had a trading volume of 301,047 shares, compared to its average volume of 169,467. The firm has a 50-day simple moving average of $1.59 and a 200-day simple moving average of $1.76. OKYO Pharma has a 1 year low of $1.34 and a 1 year high of $3.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in shares of OKYO Pharma in the 3rd quarter worth approximately $31,000. XTX Topco Ltd purchased a new position in shares of OKYO Pharma in the 4th quarter valued at approximately $36,000. Finally, Renaissance Technologies LLC boosted its position in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on OKYO shares. HC Wainwright dropped their price objective on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.67.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.